NASDAQ:CLRB - Cellectar Biosciences Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.86 -0.14 (-7.00 %) (As of 05/20/2019 04:00 PM ET)Previous Close$2.00Today's Range$1.78 - $2.0052-Week Range$1.22 - $12.76Volume402,187 shsAverage Volume1.04 million shsMarket Capitalization$9.49 millionP/E RatioN/ADividend YieldN/ABeta1.22 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) multiple myeloma (MM) and a range of B-cell malignancies, as well as in Phase I clinical study for R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is targeted to treat solid tumors. It has collaborative PDC programs with Pierre Fabre to develop CLR 1800 Series; Avicenna Oncology GMBH to develop CLR 2000 Series; Onconova Therapeutics, Inc. to develop CLR 2100 and 2200 Series; and Orano Med to develop novel PDCs. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey. Receive CLRB News and Ratings via Email Sign-up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CLRB Previous Symbol CUSIPN/A CIK1279704 Webwww.cellectar.com Phone608-441-8120Debt Debt-to-Equity Ratio0.06 Current Ratio5.04 Quick Ratio5.04Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.58 per share Price / Book1.18Profitability EPS (Most Recent Fiscal Year)($4.66) Net Income$-13,240,000.00 Net MarginsN/A Return on Equity-169.87% Return on Assets-115.68%Miscellaneous Employees7 Outstanding Shares5,100,000Market Cap$9.49 million Next Earnings Date8/9/2019 (Estimated) OptionableNot Optionable Cellectar Biosciences (NASDAQ:CLRB) Frequently Asked Questions What is Cellectar Biosciences' stock symbol? Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB." When did Cellectar Biosciences' stock split? How did Cellectar Biosciences' stock split work? Cellectar Biosciences shares reverse split on Tuesday, July 17th 2018. The 1-10 reverse split was announced on Friday, July 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 13th 2018. An investor that had 100 shares of Cellectar Biosciences stock prior to the reverse split would have 10 shares after the split. How were Cellectar Biosciences' earnings last quarter? Cellectar Biosciences Inc (NASDAQ:CLRB) announced its quarterly earnings results on Monday, May, 6th. The biopharmaceutical company reported ($0.76) EPS for the quarter, missing analysts' consensus estimates of ($0.74) by $0.02. View Cellectar Biosciences' Earnings History. When is Cellectar Biosciences' next earnings date? Cellectar Biosciences is scheduled to release their next quarterly earnings announcement on Friday, August 9th 2019. View Earnings Estimates for Cellectar Biosciences. What price target have analysts set for CLRB? 2 Wall Street analysts have issued 12-month target prices for Cellectar Biosciences' stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate Cellectar Biosciences' share price to reach $4.00 in the next twelve months. This suggests a possible upside of 115.1% from the stock's current price. View Analyst Price Targets for Cellectar Biosciences. What is the consensus analysts' recommendation for Cellectar Biosciences? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectar Biosciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellectar Biosciences. Has Cellectar Biosciences been receiving favorable news coverage? Press coverage about CLRB stock has trended somewhat negative on Monday, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cellectar Biosciences earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. Who are some of Cellectar Biosciences' key competitors? Some companies that are related to Cellectar Biosciences include KemPharm (KMPH), BIOLINERX LTD/S (BLRX), Sienna Biopharmaceuticals (SNNA), Aerpio Pharmaceuticals (ARPO), ContraFect (CFRX), Generex Biotechnology (GNBT), Melinta Therapeutics (MLNT), Aptevo Therapeutics (APVO), ProPhase Labs (PRPH), Oncomed Pharmaceuticals (OMED), Sernova (SEOVF), Leap Therapeutics (LPTX), Addex Therapeutics (ADDXF), Oncolytics Biotech (ONCY) and DiaMedica Therapeutics (DMAC). What other stocks do shareholders of Cellectar Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International (S), Bombardier (BDRBF), Encana (ECA), Bombardier, Inc. Class B (BBD.B), Bonavista Energy (BNP) and Hudbay Minerals (HBM). Who are Cellectar Biosciences' key executives? Cellectar Biosciences' management team includes the folowing people: Mr. James V. Caruso, Pres, CEO & Director (Age 60)Mr. Jarrod Longcor, Chief Bus. Officer (Age 46)Mr. Charles T. Bernhardt, Interim Chief Financial Officer (Age 58)Gregory J. Lynch, Sec. Who are Cellectar Biosciences' major shareholders? Cellectar Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include Morgan Stanley (1.04%). Company insiders that own Cellectar Biosciences stock include James V Caruso, Jarrod Longcor, John Neis and Stephen A Hill. View Institutional Ownership Trends for Cellectar Biosciences. Which major investors are selling Cellectar Biosciences stock? CLRB stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley. View Insider Buying and Selling for Cellectar Biosciences. How do I buy shares of Cellectar Biosciences? Shares of CLRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Cellectar Biosciences' stock price today? One share of CLRB stock can currently be purchased for approximately $1.86. How big of a company is Cellectar Biosciences? Cellectar Biosciences has a market capitalization of $9.49 million. The biopharmaceutical company earns $-13,240,000.00 in net income (profit) each year or ($4.66) on an earnings per share basis. Cellectar Biosciences employs 7 workers across the globe. What is Cellectar Biosciences' official website? The official website for Cellectar Biosciences is http://www.cellectar.com. How can I contact Cellectar Biosciences? Cellectar Biosciences' mailing address is 100 CAMPUS DRIVE, FLORHAM PARK NJ, 07932. The biopharmaceutical company can be reached via phone at 608-441-8120 or via email at [email protected] MarketBeat Community Rating for Cellectar Biosciences (NASDAQ CLRB)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 147 (Vote Outperform)Underperform Votes: 131 (Vote Underperform)Total Votes: 278MarketBeat's community ratings are surveys of what our community members think about Cellectar Biosciences and other stocks. Vote "Outperform" if you believe CLRB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLRB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/20/2019 by MarketBeat.com StaffFeatured Article: Is the Dow Jones Industrial Average (DJIA) still relevant? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.